OraSure Technologies and AbbVie agree to early termination of HCV co-promotion agreement
OraSure Technologies announced that OraSure and AbbVie have mutually agreed to an early termination of their Master Program Services and Co-Promotion Agreement whereby the companies have been co-promoting OraSure’s OraQuick® HCV Rapid Antibody Test in the U.S. July 01, 2016